Background Daratumumab showed encouraging efficacy as monotherapy in patients with
heavily pretreated multiple myeloma in the GEN501 and SIRIUS studies. Here we report a …

The treatment of multiple myeloma has evolved markedly in the last decade, but mortality
remains high, emphasizing the need for more effective therapies. Daratumumab, a fully …

Daratumumab is an anti-CD38 monoclonal antibody indicated for the treatment of
relapsed/refractory multiple myeloma [Citation 1–4]. Infusion-related reactions (IRRs) are …

Daratumumab is an anti-CD38 monoclonal antibody that has transformed the landscape of
treatment both for transplant-eligible and-ineligible patients with newly diagnosed multiple …

Abstract Background: Daratumumab (dara), a human CD38-directed monoclonal antibody
indicated for the treatment of patients (pts) with multiple myeloma (MM) who have received≥ …

Introduction: Daratumumab (DARA) is a CD38-targeting IgGκ monoclonal antibody with
antimyeloma activity mediated by both on-tumor and immunomodulatory mechanisms of …

Abstract Background: Daratumumab (DARA)(HuMax™-CD38), a human IgG1κ monoclonal
antibody effectively mediates destruction of CD38-expressing malignant plasma cells. In the …

Background: Dara is a monoclonal anti‐CD38 antibody approved for the treatment of
relapsed and refractory MM, but is associated with an infusion related reaction (IRR) rate of …

Introduction: Daratumumab (DARA) has potent single agent activity in relapsed/refractory
multiple myeloma (RRMM). The effectivity of DARA is partially dependent on the expression …

Background: Daratumumab-refractory multiple myeloma (MM) patients have limited
treatment options and a dire prognosis. Daratumumab (Dara) targets the overexpressed …